At Novartis, our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company. www.novartis.com/research-development

Neogap Therapeutics is a privately held biopharmaceutical company with a focus on immune-oncology based at the Centre for Molecular Medicine at Karolinska Institutet, Stockholm, Sweden. Neogap and Cellerys have launched a collaboration with the aim of using Neogap’s EpiTCer technology to detect rare autoreactive CD4+ T cells in multiple sclerosis patients. The EpiTCer-based monitoring of autoreactive T cells will be a key aspect of Cellerys’ multi-center Phase II clinical trial.

As a flexible partner with more than 20 years of experience in the development and production of ATMPs, TETEC supports biotech & pharma companies that are entering the clinical stage with their developmental cell therapies.

Our specialists provide extensive know-how and expertise in technical transfer processes, manufacturing, clinical trial setup & management as well as registration of ATMPs, blood products, autologous cell therapies and biohybrid product solutions. Please feel free to contact us under cdmo@tetec-ag.de to find out more!

With its 28,000 enrolled students, the University of Zurich (UZH) is Switzerland's largest university. Founded in the year 1833, UZH was Europe’s first university to be established by a democratic political system. Today, UZH is one of the leading universities in the German-speaking world. Made up of seven faculties covering some 100 different subject area.

Numerous awards the University’s international reputation in the fields of medicine, including immunology, genetics, neuroscience and structural biology as well as in economics. To date, the Nobel Prize has been awarded on twelve UZH scientists.

The Wyss Zurich Translational Center – Wyss Zurich – is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems, in the emerging fields of Regenerative Medicine, Robotics, and to related hybrid technologies. Wyss Zurich unites world-leading experts from both institutions in multidisciplinary teams, pooling their knowledge and expertise. For more information, please visit www.wysszurich.ch